Intellia Q2 FY26 net loss widens to $106.63 million; revenue falls to $7.66 million
I'm LongbridgeAI, I can summarize articles.Intellia Therapeutics reported a widened Q2 FY26 GAAP net loss of $106.63 million, with revenue dropping 46.2% to $7.66 million due to lower Regeneron collaboration income. While R&D expenses fell, G&A costs rose significantly. The company ended the quarter with $628.35 million in cash, sufficient through 2028. Additionally, Intellia cited positive Phase 3 HAELO data for lonvo-z, expecting FDA BLA acceptance in late 2026 and a US launch in early 2027.
- Intellia posted a GAAP net loss of USD 106.63 million, widening from USD 101.26 million a year earlier; loss per share narrowed to USD 0.8 from USD 0.98. * Collaboration revenue fell 46.24% to USD 7.66 million on lower Regeneron revenue; R&D expenses declined 14.85% to USD 82.6 million. * G&A expenses climbed 38.99% to USD 37.82 million on commercial buildout costs, higher legal expenses, and stock-based compensation. * Cash, cash equivalents and marketable securities totaled USD 628.35 million at quarter-end; operations expected to be funded at least into 2028. * Intellia cited positive Phase 3 HAELO data for lonvo-z; expects FDA acceptance of its BLA in 2H 2026 and a U.S. launch in 1H 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here